Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Change in Account Payables (2021 - 2025)

SAB Biotherapeutics' Change in Account Payables history spans 5 years, with the latest figure at $324527.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 45.03% year-over-year to $324527.0; the TTM value through Dec 2025 reached $1.5 million, up 60.59%, while the annual FY2025 figure was $1.5 million, 60.59% up from the prior year.
  • Change in Account Payables reached $324527.0 in Q4 2025 per SABSW's latest filing, down from $335924.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.8 million in Q2 2021 to a low of -$3.8 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$190205.4, with a median of $134618.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: plummeted 94287.71% in 2023, then surged 658.16% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $338327.0 in 2021, then tumbled by 100.7% to -$2367.0 in 2022, then tumbled by 4368.65% to -$105773.0 in 2023, then soared by 658.16% to $590385.0 in 2024, then plummeted by 45.03% to $324527.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Change in Account Payables are $324527.0 (Q4 2025), $335924.0 (Q3 2025), and $138171.0 (Q2 2025).